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Epilepsy is one of the most important diseases of nervous system that involves 0.5-1% of the population. In 
spite of new developments in antiepileptic drugs, between 20-30% of epileptic patients can not be controlled 
and even those who are controlled with antiepileptic drugs suffer from their adverse events. Epileptic patients 
have different challenges in relation to the disease and its medications. This article has reviewed these 
challenges. The most common challenges are misdiagnosis of epilepsy or type of epilepsy resulting in wrong 
drug administration, noncompliance with antiepileptic drugs, adverse effects of antiepileptic drugs, drug 
resistance, non-pharmacological interventions and their limitations, photosensitivity, epilepsy problems in 
children and the elderly, pregnancy and epilepsy, driving and epilepsy and finally sudden death in epileptic 
patients.  
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